ClinicalTrials.gg
RecruitingNCT07646145Updated Nov 3, 2026

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

A Phase 2 interventional study of Disitamab Vedotin and Mitomycin C (MMC) in Non-Muscle-Invasive Bladder Cancer (NMIBC), sponsored by Shanxi Province Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Shanxi Province Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Apr 2024, registered Jun 2026).
  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 3, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
35th of 47
50 · median 114
Started
2024
with 11 others
Phase 2
13 of 50
10 open now
Primary completion
2027-04
later than 22 of 43 live
Registered
45th of 50
by date

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 35th largest by planned enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 22 of the 43 other live ones, and was the 45th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression. The goal is to provide a new treatment option for NMIBC patients, reduce the risk of tumor recurrence, decrease the proportion of radical bladder surgery, and improve the quality of life of patients.

03

Conditions studied

  • Non-Muscle-Invasive Bladder Cancer (NMIBC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation, signing a written form;
  • The age on the date of signing the informed consent form should be no less than 18 years old, regardless of gender;
  • The subjects have completed the standard TURBT procedure before signing the informed consent form, and no obvious residual tumor lesions were found in the surgical field;
  • The postoperative pathology clearly diagnosed as non-muscle-invasive bladder cancer, and the main tissue component was more than 50% urothelial carcinoma (transitional cell carcinoma);
  • The subjects were classified into the intermediate-risk or high-risk group according to the risk classification for NMIBC;
  • Tumor tissue samples for TURBT must be provided, along with the required relevant pathological reports. Fresh surgical tissues or pathological slides can be sent for examination as well;
  • The patients were intolerant to BCG or did not accept the BCG infusion treatment plan;
  • Before treatment, detection was conducted on the resection specimens in the laboratory: The IHC results confirmed HER2 expression (defined as: IHC 1+, 2+ or 3+);
  • Clinical non- bladder cancer (N0, M0) was determined by abdominal computed tomography (CT).

Exclusion criteria

Exclusion Criteria:

  • History of muscle-invasive bladder cancer or bladder cancer before treatment;History of muscle-invasive bladder cancer or metastatic bladder cancer before treatment;
  • Imaging results within 3 months before treatment indicated lymph node or other site/organ metastasis;
  • Imaging results within 3 months before treatment indicated the presence of other urinary system tumors;
  • Received other systemic anti-cancer treatments within 3 weeks before treatment, including chemotherapy, biological therapy, immunotherapy, targeted therapy, endocrine therapy, and/or drug therapy;
  • Received bladder radiotherapy for urothelial carcinoma before treatment;
  • Known to have anaphylaxis or delayed allergic reaction to certain components of vedacitinib or similar drugs;
  • Within the 3 days prior to the first infusion, the following conditions had not yet been alleviated to grade 1:Uncontrolled acute or chronic infections, such as pneumonia, biliary tract infections; and infections; dyspnea;Acute or chronic kidney injury; nephrotic syndrome; bladder perforation; urinary tract obstruction;
  • rating of 3 or 4;
  • Symptoms and signs related to cardiovascular diseases: including myocardial infarction, congestive heart failure, arrhythmia, etc.;
  • Known cerebrovascular accidents;
  • History of diseases (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, hemolytic anemia, rheumatoid arthritis, etc.);
  • Known positive serology, Hepatitis C infection and/or Hepatitis B (HepBsAg or core antibody positive and responding after antiviral treatment for Hepatitis B, except for these patients: these patients are allowed to participate in this study; Note: Patients with negative HepBsAg at screening)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin Plus Intravesical Mitomycin C

    Participants will receive intravenous disitamab vedotin in combination with intravesical mitomycin C according to the protocol-defined treatment schedule.

    Drug: Disitamab Vedotin · Drug: Mitomycin C (MMC)

Interventions

  • Disitamab Vedotin injection: 2.0 mg/kg, every two weeks, treatment lasts for 8 to 12 cycles

  • DrugMitomycinStudies of MitomycinMitomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mitomycin bladder intravesical instillation: 40mg per dose. Instill immediately after surgery, then once a week thereafter. The induction chemotherapy instillation lasts for 8 times. Subsequently, it is instilled once a month for a total of 10 months for maintenance chemotherapy.

06

What researchers measure

Primary outcomes

  1. 1-year disease-free survival rate(1-year DFS rate)

    defined as the time from study treatment initiation to disease recurrence (confirmed by cystoscopic biopsy or imaging), disease progression (muscle invasion or distant metastasis), or death from any cause, estimated by the Kaplan-Meier method.

    Time frame: At 12 months after the first study treatment.

Secondary outcomes

  1. Disease-free survival

    Disease-free survival is defined as the time from the date of first study treatment to the first documented recurrence, disease progression, death from any cause, or last disease assessment, whichever occurred first.

    Time frame: From drug combination to the first documented recurrence, disease progression, death from any cause, or last follow-up, assessed up to 12 months.

  2. Overall Survival(OS)

    Overall survival is defined as the time from the date of first study treatment to death from any cause. Participants who are alive at the last follow-up will be censored at the date of last known follow-up.

    Time frame: From the date of first study treatment to the date of death from any cause or last known follow-up, whichever occurred first, assessed up to 12 months.

  3. Incidence and Severity of Treatment-emergent Adverse Events

    Treatment-emergent adverse events are defined as adverse events that occur or worsen after initiation of study treatment. Adverse events will be recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: From the date of first study treatment until 30 days after the last dose of study treatment, assessed up to 12 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 12, 2026
StartActual
Apr 1, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
30→50
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Enrollment 30→50

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646145
Lead sponsor
Shanxi Province Cancer Hospital
Responsible party
hanxuebin (Director of Urology Department, Shanxi Province Cancer Hospital) — Principal investigator
First posted
Jun 12, 2026
Start date
Apr 1, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Xuebing Han
Contact
hanxuebing808@126.com
86+17861282270

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion